Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2022-06-06 5:10 pm Purchase | 2022-06-03 | 13D | Kodiak Sciences Inc. KOD | Baker Bros. Advisors LP | 17,353,846 33.400% | 922,755 (+5.62%) | Filing History |
| 2022-05-18 5:23 pm Purchase | 2022-05-16 | 13D | Kodiak Sciences Inc. KOD | Baker Bros. Advisors LP | 16,431,091 31.600% | 865,023 (+5.56%) | Filing History |
| 2022-05-12 4:45 pm Purchase | 2022-05-10 | 13D | TScan Therapeutics, Inc. TCRX | Baker Bros. Advisors LP | 2,784,792 14.700% | 1,359,792 (+95.42%) | Filing History |
| 2022-04-05 5:15 pm Purchase | 2022-03-29 | 13D | IGM Biosciences, Inc. IGMS | Baker Bros. Advisors LP | 3,169,894 11.600% | 12,110 (+0.38%) | Filing History |
| 2022-03-10 5:20 pm Purchase | 2022-03-08 | 13D | Incyte Corporation INCY | Baker Bros. Advisors LP | 36,634,354 16.500% | 1,417,736 (+4.03%) | Filing History |
| 2022-03-10 4:40 pm Sale | 2022-03-08 | 13D | Seagen Inc. SGEN | Baker Bros. Advisors LP | 47,223,608 25.700% | -394,895 (-0.83%) | Filing History |
| 2022-02-14 4:20 pm Purchase | 2022-02-10 | 13D | Incyte Corporation INCY | Baker Bros. Advisors LP | 35,216,618 15.900% | 2,692,198 (+8.28%) | Filing History |
| 2022-02-14 4:17 pm Sale | 2021-12-31 | 13G | Invitae Corporation NVTAQ | Baker Bros. Advisors LP | 9,873,488 4.400% | -5,900,607 (-37.41%) | Filing History |
| 2022-02-14 4:17 pm Purchase | 2021-12-31 | 13G | Rhythm Pharmaceuticals, Inc. RYTM | Baker Bros. Advisors LP | 3,863,239 7.700% | 1,548,366 (+66.89%) | Filing History |
| 2022-02-14 4:16 pm Purchase | 2021-12-31 | 13G | Otonomy, Inc. OTIC | Baker Bros. Advisors LP | 7,844,692 13.800% | 624,618 (+8.65%) | Filing History |
| 2022-02-14 4:16 pm Purchase | 2021-12-31 | 13G | Zymeworks Inc. ZYME | Baker Bros. Advisors LP | 4,977,296 9.990% | 67,486 (+1.37%) | Filing History |
| 2022-02-14 4:16 pm Purchase | 2021-12-31 | 13G | Mereo BioPharma Group plc MREO | Baker Bros. Advisors LP | 64,917,601 9.990% | 25,285,672 (+63.80%) | Filing History |
| 2022-02-14 4:16 pm Purchase | 2021-12-31 | 13G | Verastem, Inc. VSTM | Baker Bros. Advisors LP | 1,790,969 11.800% | 233,828 (+15.02%) | Filing History |
| 2022-02-14 4:15 pm Purchase | 2021-12-31 | 13G | Surrozen, Inc. SRZN | Baker Bros. Advisors LP | 222,222 9.300% | 222,222 (New Position) | Filing History |
| 2022-02-14 4:15 pm Purchase | 2021-12-31 | 13G | BioCryst Pharmaceuticals, Inc. BCRX | Baker Bros. Advisors LP | 18,464,744 9.950% | 285,863 (+1.57%) | Filing History |
| 2022-02-14 4:15 pm Sale | 2021-12-31 | 13G | OPTHEA LTD SPONSORED ADR OPTEY | Baker Bros. Advisors LP | 26,427,521 7.500% | -7,535,719 (-22.19%) | Filing History |
| 2022-02-14 4:15 pm Purchase | 2021-12-31 | 13G | Nurix Therapeutics, Inc. NRIX | Baker Bros. Advisors LP | 2,454,082 5.500% | 2,454,082 (New Position) | Filing History |
| 2022-02-14 4:15 pm Purchase | 2021-12-31 | 13G | Heron Therapeutics, Inc. HRTX | Baker Bros. Advisors LP | 8,131,678 8.000% | 66,846 (+0.83%) | Filing History |
| 2022-02-14 4:14 pm Purchase | 2021-12-31 | 13G | Immatics N.V. IMTX | Baker Bros. Advisors LP | 4,423,731 7.000% | 4,423,731 (New Position) | Filing History |
| 2022-02-14 4:14 pm Purchase | 2021-12-31 | 13G | Global Blood Therapeutics, Inc. GBT | Baker Bros. Advisors LP | 3,314,765 5.100% | 3,314,765 (New Position) | Filing History |